- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Union Health Minister reviews availability of COVID essential drugs, buffer stocks
The strategic buffer stock has been created for 8 drugs, all of these are available in the country.
New Delhi: Union Minister for Health and Family Welfare and Chemicals and Fertilisers, Mansukh Mandaviya reviewed the supply and availability of COVID-19 related essential medicines in the country.During the review, it was noted that sufficient stocks of all the essential medicines are available. Raw materials for these drugs are also available in enough quantities.Also Read: Union...
New Delhi: Union Minister for Health and Family Welfare and Chemicals and Fertilisers, Mansukh Mandaviya reviewed the supply and availability of COVID-19 related essential medicines in the country.
During the review, it was noted that sufficient stocks of all the essential medicines are available. Raw materials for these drugs are also available in enough quantities.
The strategic buffer stock has been created for 8 drugs, all of these are available in the country. Here is the list of 8 drugs:
1. Tocilizumab
2. Methyl Predinisolone
3. Enaxopirin
4. Dexamethasone
5. Remdesivir
6. Amphotericin B Deoxycholate
7. Posaconazole
8. Intravenous Immunoglobilin (IVIG)
Senior Officials of the Ministry of Health and Family Welfare were present in the review meeting.